签署日期： 年 月 日 因此，我们一致同意将该事项提交公司第六届董事会第三次会议审议。 （本页无正文，为《石药集团新诺威制药股份有限公司独立董事关于第六届董事 会第三次会议相关事项的事前认可意见》之签署页） 李迪斌 杨鹏 邸丛枝 石药集团新诺威制药股份有限公司独立董事 关于第六届董事会第三次会议相关事项的事前认可意见 根据《公司章程》及《独立董事工作细则》等制度的相关规定，并参照《关 于在上市公司建立独立董事制度的指导意见》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》等法律、法规、规范性文件的规定，我们作为石药集团新诺威制药股份有 限公司（以下简称"公司"）独立董事，本着勤勉、尽责的态度，基于独立的立场 及判断，已于会前获悉本次会议审议的相关事项并进行了事前审议。 公司本次增加与关联方石家庄世耀工程有限公司的日常关联交易预计额度 系公司日常经营所需，交易事项符合市场经营规则，交易定价公允，不存在损害 公司及股东利益，特别是中小股东利益的情形，符合《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 7 号——交易与关 ...

证券代码：300765 证券简称：新诺威 公告编号：2023-055 石药集团新诺威制药股份有限公司 关于增加 2023 年度日常关联交易预计额度的公告 （一）2023 年度日常关联交易概述 1、石药集团新诺威制药股份有限公司（以下简称"公司"）于 2022 年 12 月 30 日召开的第五届董事会第二十六次会议和 2023 年 1 月 16 日召开的 2023 年第 一次临时股东大会审议通过了《关于公司 2023 年度日常性关联交易预计的议案》。 2、公司于 2023 年 8 月 16 日召开的第六届董事会第三次会议审议通过《关 于增加 2023 年度日常关联交易预计额度的议案》，综合考虑公司后续业务情况， 公司决定增加与关联方石家庄世耀工程有限公司的日常关联交易预计额度。关联 董事潘卫东、王怀玉、CAI LEI、姚兵、杨栋已对此议案回避表决。公司独立董 事对本次关联交易事项发表了事前认可意见以及独立意见。根据《深圳证券交易 所创业板股票上市规则》，公司本次增加 2023 年度日常关联交易预计金额未超过 公司最近一期经审计净资产绝对值 5%以上，无需提交公司股东大会审议。 单位：万元 | 关联交 | 关联方 ...

石药集团新诺威制药股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》和石药集团新诺威制药股份有限公司（以下简称"新诺威"或"公司"） 《募集资金管理办法》的有关规定，现将公司 2023 年半年度募集资金存放与使 用情况专项说明如下： 上述募集资金到位情况已由信永中和会计师事务所（特殊普通合伙）审验， 并于 2023 年 2 月 22 日出具《验资报告》（报告号：XYZH/2023HZAA1B0061）。 公司已对募集资金采取了专户存储，并且公司与开户银行、独立财务顾问签订了 《募集资金三方监管协议》。 2、截至 2023 年 6 月 30 日募集资金净额使用情况及结余情况 一、募集资金基本情况 1、募集资金金额、资金到账时间 （1）首次公开发行募集资金情况 石药集团新诺威制药股份有限公司经中国证券监督管理委员会《关于核准石 药集团新诺威制药股份有限公司首次公开发行股票的批复》（证监许可[2019]288 号）核准，并经深圳证券交易所《关于石药集团新诺威制药股份有限公司人民币 普通股股票在创业板上市的通知》（深证上[ ...

证券代码： 300765 证券简称： 新诺威 石药集团新诺威制药股份有限公司投资者关系活动记录表 编号：2023-03 √特定对象调研 □分析师会议 投资者关系活 □媒体采访 □业绩说明会 动类别 □新闻发布会 □路演活动 □现场参观 □其他 | --- | --- | |--------------|------------------------------------------------------| | | 国信证券彭思语、国寿安保基金王雪莹、招银理财吴昆伦、 | | 参与单位名称 | 中信建投资管王晨宇、安信基金陈少波、华夏东方养老资产 | | | 管理有限公司蔡颖 | 时间 2023 年 6 月 7 日 (周三) 上午 9:30~10:30 地点 公司会议室 上市公司接待 人员姓名 董事会秘书兼财务总监：戴龙 一、对公司基本情况进行介绍。 二、互动问答。 问题 1、咖啡因业务的政策法规。 答复：咖啡因产品属于国家第二类精神药品，国家药品 监督管理部门对精神药品实行定点生产制度。需严格按照 投资者关系活 《麻醉药品和精神药品管理条例》进行生产和销售。根据河 动主要内容介 北省药品监督管理局每年出 ...

证券代码： 300765 证券简称： 新诺威 石药集团新诺威制药股份有限公司投资者关系活动记录表 编号：2023-02 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投 资者关 系活 □新闻发布会 □路演活动 动类别 □现场参观 √其他 2023 年河北辖区上市公司投 资者网上集体接待日活动 参与单位名称 投资者网上提问 时间 2023 年 5 月 30 日 (周二) 下午 14:00~17:00 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 用网络远程的方式参加了由中国证监会河北监管局举办的 地点 2023 年河北辖区上市公司投资者网上集体接待日活动 上 市公司 接待 1、董事会秘书兼财务总监戴龙 2、财务负责人耿君霞 人员姓名 公司于 2023 年 5 月 30 日（周二）14:00—17:00 参加由 中国证监会河北监管局举办的 2023 年河北辖区上市公司投 资者网上集体接待日活动，本次活动采用网络远程的方式举 行。 投 资者关 系活 投资者提出的问题及公司回复情况 动 主要内 容介 公司就投资者在本次活动中提出的问题进行了回复： 绍 1、请问贵司如何看待后 ...

证券代码：300765 证券简称：新诺威 公告编号：2023-047 石药集团新诺威制药股份有限公司 关于参加河北辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，石药集团新诺威制药股份有限公司（以 下简称"公司"）将参加由河北证监局、河北省上市公司协会与深圳市全景网络 有限公司联合举办的"2023 年河北辖区上市公司投资者集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参与 本次互动交流，活动时间为 2023 年 5 月 30 日（周二） 15:40-17:00。届时公司 高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况等投资者关 心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 石药集团新诺威制药股份有限公司 董事会 2023 年 5 月 26 日 1 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥684,020,305, representing a 26.43% increase compared to ¥541,028,381 in the same period last year[5] - Net profit attributable to shareholders was ¥181,976,426, a 47.33% increase from ¥123,520,129 in Q1 2022[5] - The net profit after deducting non-recurring gains and losses was ¥179,439,429, reflecting a 60.88% increase from ¥111,537,005 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 684,020,305, representing an increase of 26.4% compared to CNY 541,028,381.87 in the same period last year[23] - Net profit for Q1 2023 reached CNY 181,929,887.41, representing a 47.2% increase from CNY 123,502,450.15 in Q1 2022[24] - The company reported a total comprehensive income of CNY 181,810,781.12 for Q1 2023, up from CNY 123,843,650.92 in the same period last year[25] - Basic and diluted earnings per share for Q1 2023 were CNY 0.2939, compared to CNY 0.1995 in Q1 2022, marking a 47.3% increase[25] Cash Flow and Liquidity - Operating cash flow net amount was ¥156,910,520, up 47.53% from ¥106,355,966 in Q1 2022[12] - Cash and cash equivalents at the end of Q1 2023 were ¥2,799,277,798, a 63.81% increase from ¥1,708,827,432 at the end of the previous year[12] - The company's cash and cash equivalents at the end of Q1 2023 amounted to CNY 2,802,092,881.57, up from CNY 2,195,684,427.95 at the beginning of the year, reflecting a growth of 27.6%[20] - The company raised CNY 488,799,998.48 through financing activities in Q1 2023, compared to a cash outflow of CNY 736,892.33 in the same period last year[28] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥5,180,768,085, a 13.02% increase from ¥4,584,035,512 at the end of the previous year[5] - The total assets as of March 31, 2023, were CNY 5,180,768,084.66, compared to CNY 4,584,035,512.38 at the beginning of the year, indicating an increase of 13.0%[21] - The total liabilities decreased from CNY 639,841,376.25 at the beginning of the year to CNY 566,567,751.88, a reduction of 11.4%[21] - The equity attributable to shareholders of the parent company increased to CNY 4,605,653,369.51 from CNY 3,935,600,634.14, marking a growth of 17.0%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,983, with the top 10 shareholders holding 73.35% of the shares[13] - The total number of unrestricted shares held by the top 10 shareholders includes 404,135,550 shares held by Shiyao Group Enbipu Pharmaceutical Co., Ltd.[14] - UBS AG holds 3,211,586 shares, representing 0.51% of the total shares[14] - The total number of shares held by the top shareholder, Shiyao Group Enbipu Pharmaceutical Co., Ltd., is 404,135,550 shares, all of which are ordinary shares[14] - The total number of shares held by Hong Kong Central Clearing Limited is 6,052,856, representing 0.93% of the total shares[14] Research and Development - The company's R&D expenses increased by 79.97% to ¥13,545,879 from ¥7,526,576 in the same period last year, indicating a focus on innovation[11] - Research and development expenses increased to CNY 13,545,879.02, up 80.5% from CNY 7,526,575.82 in the previous year[24] Operational Highlights - The company completed the election of a new board of directors and supervisory board on April 7, 2023, along with the appointment of new senior management[18] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[18] - Total operating costs for Q1 2023 were CNY 472,576,687.19, an increase of 22.4% compared to CNY 386,256,108.97 in Q1 2022[24] - The company experienced a foreign exchange loss of CNY 4,787,109.33 during Q1 2023, compared to a gain of CNY 81,750.42 in Q1 2022[28]

Financial Performance - The company's revenue for Q1 2023 reached ¥684,020,305, representing a 26.43% increase compared to ¥541,028,381 in the same period last year[5] - Net profit attributable to shareholders was ¥181,976,426, a 47.33% increase from ¥123,520,129 in Q1 2022[5] - Basic and diluted earnings per share increased to ¥0.2939, reflecting a 47.32% rise from ¥0.1995 in Q1 2022[5] - Total operating revenue for the current period reached ¥684,020,305, an increase of 26.4% compared to ¥541,028,381 in the previous period[26] - Net profit for the current period was ¥181,929,887, representing a 47.3% increase from ¥123,502,450 in the previous period[27] - The total profit for the current period was ¥215,261,824, an increase of 42.8% from ¥150,720,084 in the previous period[27] Cash Flow and Liquidity - The net cash flow from operating activities was ¥156,910,519, up 47.53% from ¥106,355,965 in the previous year[14] - Cash flow from operating activities generated a net amount of ¥156,910,520, compared to ¥106,355,966 in the previous period, marking a 47.5% increase[30] - The cash and cash equivalents balance at the end of the quarter was ¥2,799,277,798, a 63.81% increase from ¥1,708,827,432 at the end of the previous year[14] - Cash and cash equivalents at the end of the period totaled ¥2,799,277,798, up from ¥1,708,827,432, indicating a significant increase of 63.8%[31] - The company experienced a cash inflow from financing activities of ¥488,514,998, a significant turnaround from a cash outflow of -¥736,892 in the previous period[31] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥5,180,768,085, a 13.02% increase from ¥4,584,035,512 at the end of the previous year[5] - In Q1 2023, the total assets of the company reached CNY 5,180,768,084.66, an increase from CNY 4,584,035,512.38 at the beginning of the year, reflecting a growth of approximately 13.0%[22] - The total liabilities decreased to CNY 566,567,751.88 from CNY 639,841,376.25, indicating a reduction of approximately 11.4%[24] - The total current liabilities decreased to CNY 509,763,945.63 from CNY 582,768,085.61, a reduction of approximately 12.5%[24] Research and Development - The company reported a 79.97% increase in R&D expenses, totaling ¥13,545,879, compared to ¥7,526,576 in Q1 2022, indicating a focus on innovation[12] - Research and development expenses rose to ¥13,545,879, a substantial increase of 80.0% from ¥7,526,576 in the previous period[26] Shareholder Information - The company reported a total of 72,926,162 shares held by its largest shareholder, Shiyao Group Enbi Pharmaceutical Co., Ltd., which accounts for a significant portion of the total shares[18] - UBS AG acquired 3,211,586 shares during the non-public offering, with a lock-up period ending on September 9, 2023[18] - The company has not released any restricted shares during this quarter, maintaining a total of 72,926,162 restricted shares[18] - The company has committed to a 36-month lock-up period for shares issued in the recent transaction, ensuring stability in shareholder structure[18] - The top ten shareholders collectively hold a significant number of unrestricted shares, indicating strong institutional support[17] Strategic Initiatives - The company plans to expand its market presence and is focusing on new product development and technological advancements[17] - The first quarter performance indicates a strong upward trend in user data and market engagement, reflecting the effectiveness of recent strategies[17] - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[17] - Future guidance suggests continued growth in revenue and user base, driven by strategic initiatives and market expansion efforts[17] Other Financial Metrics - Accounts receivable financing increased by 51.25% to ¥172,533,899 due to higher revenue and increased bank acceptance bills received[10] - The company experienced a 35.50% decrease in contract liabilities, down to ¥44,025,922, attributed to a reduction in advance payments received[10] - The company's accounts receivable decreased to CNY 439,056,492.37 from CNY 481,379,233.73, a decline of approximately 8.8%[23] - The inventory level decreased to CNY 229,119,007.12 from CNY 238,125,791.53, reflecting a decrease of about 3.8%[23] - The company's long-term investments slightly decreased to CNY 252,784,264.20 from CNY 253,488,895.12, a minor decline of about 0.3%[23]

石药集团新诺威制药股份有限公司（以下简称"公司"）已于 2023 年 3 月 17 日披露公司《2022 年年度报告》，为使投资者进一步了解公司的财务状况、经 营情况及公司发展规划，公司定于 2023 年 4 月 4 日（星期二）15:00-17:00 在全 景网举办 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举 行，投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次 年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长潘卫东先生、董事兼总经理 韩峰先生、独立董事徐一民先生、董事会秘书兼财务总监杜英女士、保荐代表人 张翊维先生。 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向投 资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 3 日 14:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。 公司将在 2022 年度网上业绩说明会上，对投资者普遍关注的问题进行回答。 证券代码：300765 证券简称：新诺威 公告编号：2023-031 石药集团新 ...